Insider Selling: Takeda Pharmaceutical (NYSE:TAK) Insider Sells $392,564.70 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Agosti Marcello Pignagnoli sold 22,957 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $392,564.70. Following the completion of the transaction, the insider directly owned 176,977 shares in the company, valued at approximately $3,026,306.70. This represents a 11.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Up 1.5%

TAK opened at $17.64 on Friday. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $56.53 billion, a price-to-earnings ratio of 51.89 and a beta of -0.08. The business has a 50 day moving average of $16.57 and a 200-day moving average of $17.14.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The business had revenue of $6.90 billion for the quarter. As a group, sell-side analysts anticipate that Takeda Pharmaceutical Co. will post 0.32 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada raised its stake in shares of Takeda Pharmaceutical by 11.0% in the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock valued at $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC boosted its stake in Takeda Pharmaceutical by 43.6% during the first quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock worth $2,911,000 after buying an additional 59,442 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares in the last quarter. Focus Partners Wealth increased its holdings in Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock valued at $1,230,000 after buying an additional 3,239 shares during the period. Finally, Sivia Capital Partners LLC acquired a new position in shares of Takeda Pharmaceutical in the 2nd quarter valued at $351,000. 9.17% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.